It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Autism spectrum disorder (ASD) is a complex behavioral disorder diagnosed by social interaction difficulties, restricted verbal communication, and repetitive behaviors. Fecal microbiota transplantation (FMT) is a safe and efficient strategy to adjust gut microbiota dysbiosis and improve ASD-related behavioral symptoms, but its regulatory mechanism is unknown. The impact of the microbiota and its functions on ASD development is urgently being investigated to develop new therapeutic strategies for ASD. We reconstituted the gut microbiota of a valproic acid (VPA)-induced autism mouse model through FMT and found that ASD is in part driven by specific gut dysbiosis and metabolite changes that are involved in the signaling of serotonergic synapse and glutamatergic synapse pathways, which might be associated with behavioral changes. Further analysis of the microbiota showed a profound decrease in the genera Bacteroides and Odoribacter, both of which likely contributed to the regulation of serotonergic and glutamatergic synapse metabolism in mice. The engraftment of Turicibacter and Alistipes was also positively correlated with the improvement in behavior after FMT. Our results suggested that successful transfer of the gut microbiota from healthy donors to ASD mice was sufficient to improve ASD-related behaviors. Modulation of gut dysbiosis by FMT could be an effective approach to improve ASD-related behaviors in patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Shanghai Tenth People’s Hospital Affiliated to Tongji University, Department of Pathology, Shanghai, China (GRID:grid.412538.9) (ISNI:0000 0004 0527 0050)
2 Shanghai Tenth People’s Hospital Affiliated to Tongji University, Intestinal Microenvironment Treatment Center, Shanghai, China (GRID:grid.412538.9) (ISNI:0000 0004 0527 0050)
3 Shanghai Tenth People’s Hospital Affiliated to Tongji University, Department of Pediatrics, Shanghai, China (GRID:grid.412538.9) (ISNI:0000 0004 0527 0050)
4 Shanghai Majorbio Bio-pharm Technology Co.,Ltd, Shanghai, China (GRID:grid.412538.9)
5 Intestinal Microenvironment Treatment Center, Shanghai Tenth People’s Hospital Affiliated to Tongji University, Department of Gastrointestinal Surgery, Shanghai Tenth People’s Hospital Affiliated to Tongji University, Shanghai, China (GRID:grid.24516.34) (ISNI:0000000123704535)